Navigation Links
First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients
Date:4/30/2009

SEATTLE, WA April 30, 2009 Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.

"There is a consensus among physicians that early initiation of effective therapy beginning shortly after symptom onset may be required to alter the long term course of MS, but until now there has been little evidence to support this hypothesis," said Dr. R. Philip Kinkel, director of the multiple sclerosis center, Beth Israel Deaconess Medical Center in Boston, MA and lead investigator of CHAMPIONS. "This data confirms that treatment of high risk patients beginning shortly after symptom-onset reduces relapse rates and may reduce disease progression for up to 10 years. This may translate into an ability to remain active and enjoy daily activities that otherwise might be lost without treatment."

The CHAMPIONS open label follow-up study was designed to determine long-term clinical outcomes and the ten-year follow up included 155 patients from 24 of the 50 Phase III CHAMPS study sites. Key findings include:

  • 40 percent reduction in conversion to CDMS in patients treated immediately upon diagnosis of CIS versus tho
    '/>"/>

Contact: Kathy Vigneault
kathleen.vigneault@mslworldwide.com
617-937-2546
Manning Selvage & Lee
Source:Eurekalert

Page: 1 2

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... to pay higher employee contributions for their health insurance, ... about the impact of the Patient Protection and Affordable ... by the Darla Moore School of Business at the ... Wright, a professor in strategic human resource management, directs ... The survey is distributed to more than 560 CHROs ...
(Date:9/18/2014)... 2014 ChopChop founder Sally Sampson ... Yonah Kalikow, 10-year-old Massachusetts’s winner of the First Lady’s Healthy ... the classic Middle Eastern bean dip. Watch as Bill and ... can create their own healthy dips at home. The cooking ... annual Let’s Talk About Food Festival in Copley ...
(Date:9/18/2014)... A sold-out crowd of more than ... supported United Way of Westchester and Putnam ... event Monday, Sept. 15. Proceeds from the event will ... and Putnam, such as providing healthy foods to low-income ... risky behaviors like drug and alcohol usage. , Two ...
(Date:9/18/2014)... broadly effective vaccines to prevent the spread of illnesses ... has been made along these lines, there are still ... from these devastating diseases. , So what are ... At Caltech, Nobel Laureate David Baltimore and his colleagues ... vaccines introduce substances such as antigens into the body ...
Breaking Medicine News(10 mins):Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News:A new way to prevent the spread of devastating diseases 2Health News:A new way to prevent the spread of devastating diseases 3Health News:A new way to prevent the spread of devastating diseases 4Health News:A new way to prevent the spread of devastating diseases 5
... Food and Drug Administration, seeking marketing authorization for Zometa ... broad range of tumor types. These include prostate and ... approved. The spread of cancerous cells from the original ... called skeletal related events like fractures, compression of ...
... more heart-friendly products has been developed by European scientists. ... UK and colleagues, describe how they boosted the production ... tomatoes. Rutin is a flavonol, part of a larger ... be a powerful antioxidant.// ,The researchers noticed ...
... As there is so much to do and remember ... uncommon. ,Many people find prolonged stress and ... and even personality changes. Dramatic alterations in memory and ... Alzheimer's disease. // ,The fundamental cause of dementia ...
... an infectious disease transmitted by mosquitoes.It is characterised by ... severe forms of this disease can lead to death ... countries.// ,Hence eradication of this disease involves the ... in southern Asia, villagers spray the inside of their ...
... with heart disease are more likely to have severe symptoms ... monthly menstrual cycle, according to new research from England. ... which occurs when there is insufficient oxygen supply to the ... of heart disease. Researchers from the Cardiothoracic Centre report in ...
... the US recommend that everyone over 65 should get a ... making you more prone to infection. That's why it may ... Mayo Clinic in the US also urge people over 65 ... you from pneumonia, meningitis, and various other serious infections. The ...
Cached Medicine News:
(Date:9/18/2014)... , September 18, 2014 ... Markets ( http://www.researchandmarkets.com/research/f9nkkh/sugar_alcohols ) has announced the addition ... Business Report"  report to their offering.  ... analyzes the worldwide markets for Sugar Alcohols ... Segments: Food & Confectionery, Pharmaceuticals, Cosmetics, Oral-Care ...
(Date:9/18/2014)... , Sept. 18, 2014  LABSCO, ... laboratory technologies and products to hospitals, physician ... today an amended distributorship agreement with Sysmex ... controls and instruments, including the Sysmex XS-1000 ... XP-300™, XT-Series and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... Sept. 18, 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today ... and full-year ended June 30, 2014. ... months ended June 30, 2014 increased $492,000, or 18%, ... months ended June 30, 2013, due primarily to an ... revenues from the Company,s largest customer, partially offset by ...
Breaking Medicine Technology:Sugar Alcohols - Global Strategic Business Report 201 2Sugar Alcohols - Global Strategic Business Report 201 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... Trial Marks Third Study in Company,s STEALTH C Clinical Program ... Nitazoxanide in the Treatment of Chronic Hepatitis C, ... company, today announced that it has begun enrolling,patients in a ... hepatitis C. Preliminary data from the study is,expected in the ...
... 17 BrainCells Inc. (BCI), a,biopharmaceutical company utilizing ... promote the growth of new neurons for the ... that it has,initiated a Phase 2a clinical trial ... of depression with anxiety., "We are encouraged ...
Cached Medicine Technology:Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 2Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 3BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety 2
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
30, 6.0mm from end...
...
Medicine Products: